---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-003881"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2022-02-11T23:59:59+00:00"
generated_at: "2026-06-27T08:51:33.969480+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO

## Summary
- Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.
- Cash and cash equivalents $18.0M as of Dec 31, 2021; cash burn $1.2M in Q2.
- Initiated Phase 2 proof-of-concept study for ANEB-001 for acute cannabinoid intoxication; topline results expected H1 2022.
- Simon Allen appointed CEO effective Feb 1, 2022; previously CBO at Ambrx.
- FDA pre-IND meeting provided guidance; U.S. patent issued for ANEB-001 (expires 2040).

## SEC filing metadata
- accession: 0001493152-22-003881
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2022-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/0001493152-22-003881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-003881
- JSON: https://secwatch.observer/filing/0001493152-22-003881.json
- Plain text: https://secwatch.observer/filing/0001493152-22-003881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.